Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

Exclusion Criteria

• •History of severe anaphylaxis to peanut per current National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) allergic reaction toxicity grading.
• •Known sensitivity or intolerance to Oats.
• •FEV1 value \<80% predicted or any clinical features of moderate or persistent asthma per 2007 National Heart Lung and Blood Institute (NHLBI) guidelines.
• •Exacerbation of asthma in the past year requiring hospitalization or greater than 1 emergency department (ED) visit for asthma in the past 6 months.
• •Use Beta-blockers, ACE inhibitors, angiotensin receptor blocker (ARB) , or calcium channel blockers, xolair, or immunological treatments.
• •Uncontrolled hypertension per JNC 7 Guidelines (BP \> 145/95 seated readings on each of two or more office visits).
• •Active eosinophilic gastrointestinal disease which could be exacerbated by peanut oral immunotherapy.
• •Chronic diseases such as diabetes, liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, blood disorders, or history of ischemic cardiovascular disease, or other conditions that in the opinion of the Investigator make the subject unsuitable for induction of food allergy reactions.
• •Unable to speak English.
• •Inability to discontinue antihistamines prior to food challenges and skin prick tests.